Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Equity-to-Asset : 0.24 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Reviva Pharmaceuticals Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5.72 Mil. Reviva Pharmaceuticals Holdings's Total Assets for the quarter that ended in Dec. 2023 was $23.70 Mil.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Equity-to-Asset or its related term are showing as below:

RVPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -2270.33 Med: 0.44 Max: 0.91
Current: 0.24

During the past 5 years, the highest Equity to Asset Ratio of Reviva Pharmaceuticals Holdings was 0.91. The lowest was -2270.33. And the median was 0.44.

RVPH's Equity-to-Asset is ranked worse than
78.21% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs RVPH: 0.24

Reviva Pharmaceuticals Holdings Equity-to-Asset Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Equity-to-Asset Chart

Reviva Pharmaceuticals Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-2,270.33

0.62

0.91

0.44

0.24

Reviva Pharmaceuticals Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial												0.44	0.45	0.14	-1.58	0.24

Competitive Comparison of Reviva Pharmaceuticals Holdings's Equity-to-Asset

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Equity-to-Asset falls into.

Reviva Pharmaceuticals Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Reviva Pharmaceuticals Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	5.719	/	23.7
	=

Reviva Pharmaceuticals Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	5.719	/	23.7
	=

Reviva Pharmaceuticals Holdings (NAS:RVPH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Reviva Pharmaceuticals Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.

Executives

Purav Patel	director	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu	officer: Chief Financial Officer	19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp	10 percent owner	250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena	director, 10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc	director, 10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat	director, 10 percent owner, officer: President and CEO	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon	officer: Chief Medical Officer	19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin	director	19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019